Loading...
•
Mar 31, 2021
Corcept Therapeutics Q1 2021 Earnings Report
Reported results for the quarter ended March 31, 2021.
Key Takeaways
Corcept Therapeutics reported a revenue of $79.4 million for Q1 2021, compared to $93.2 million in Q1 2020. GAAP net income was $23.5 million, or $0.18 per share, compared to $30.1 million, or $0.25 per share, in the same quarter of the previous year. Non-GAAP net income was $25.8 million, or $0.20 per share, compared to $41.2 million, or $0.34 per share, in the first quarter of 2020.
Revenue was $79.4 million, compared to $93.2 million in first quarter 2020
GAAP diluted net income was $0.18 per share, compared to $0.25 per share in first quarter 2020
Non-GAAP diluted net income was $0.20 per share, compared to $0.34 per share in first quarter 2020
Cash and investments totaled $454.8 million, compared to $476.9 million at December 31, 2020
Forward Guidance
Corcept modified its 2021 revenue guidance to $355 – $385 million and anticipates positive cash flow for the foreseeable future.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...